✦ LIBER ✦

106 International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (copegus®)

✍ Scribed by Stefan Zeuzem; Moisés Diago; Edward Gane; Rajender Reddy; Paul Pockros; Patrizia Farci; Norman Lardelli; Mitchell Shiffman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

503 Early prediction of sustained virolo

✍ P.J. Pockros; M. Diago; E. Gane; K.R. Reddy; D. Prati; M.L. Shiffman; P. Farci; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 65 KB

PGI5 COST-EFFECTIVENESS OF TREATING ADUL

✍ J Hornberger; P Farci; D Prati; S Zuezem; KK Patel; J Green 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PIN3 COST-EFFECTIVENESS ANALYSIS OF COMB

✍ C Rubio Terres; C Álvarez Sanz; KK Patel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

987 Peginterferon alfa-2A (40KD) (PEGASY

✍ HERNANDEZQUERO, J; PEREZGUZMAN, E; LOZANO, F; PARRA, J; DELMARALONSO, M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

187 Efficacy and safety of 22 weeks of m

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Pegeinterferon alfa-2a (40 KD) (Pegasys)

✍ P. Marcellin; S. Brillanti; H. Cheinquer; W.G.E. Cooksley; M.L. Shiffman; W.E. S 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 125 KB